Research Article
mHealth for Medication and Side Effect Monitoring: Patients’ Attitudes Toward Smart Devices for Managing Oral Chemotherapy During Lung Cancer Treatment
@INPROCEEDINGS{10.1007/978-3-031-34586-9_38, author={Anna N. Baglione and Sarah Tolman and Chloe Dapaah and Danielle Johnson and Kristen J. Wells and Richard D. Hall and Ryan D. Gentzler and Laura E. Barnes}, title={mHealth for Medication and Side Effect Monitoring: Patients’ Attitudes Toward Smart Devices for Managing Oral Chemotherapy During Lung Cancer Treatment}, proceedings={Pervasive Computing Technologies for Healthcare. 16th EAI International Conference, PervasiveHealth 2022, Thessaloniki, Greece, December 12-14, 2022, Proceedings}, proceedings_a={PERVASIVEHEALTH}, year={2023}, month={6}, keywords={mHealth smartphone medication adherence side effect cancer}, doi={10.1007/978-3-031-34586-9_38} }- Anna N. Baglione
Sarah Tolman
Chloe Dapaah
Danielle Johnson
Kristen J. Wells
Richard D. Hall
Ryan D. Gentzler
Laura E. Barnes
Year: 2023
mHealth for Medication and Side Effect Monitoring: Patients’ Attitudes Toward Smart Devices for Managing Oral Chemotherapy During Lung Cancer Treatment
PERVASIVEHEALTH
Springer
DOI: 10.1007/978-3-031-34586-9_38
Abstract
In recent years, new treatments have become available which have improved survival rates in lung cancer patients. One promising treatment option is the rapidly growing field of oral targeted therapies, which employs drugs that interfere with specific molecules involved in the growth, progression, and spread of cancer. However, these therapies can cause a variety of symptoms and adverse events that can impair quality of life. mHealth technologies may help individuals with lung cancer better track their side effects and manage medications on a day-to-day basis. However, understanding patients’ attitudes toward smart devices such as smartphones, smartwatches, and smart pill bottles, as well as their specific needs when using these devices, is critical before design and deployment studies of medication adherence can be carried out. In this study, we conducted interviews with 9 individuals with stage III-IV lung cancer at a National Cancer Institute-designated comprehensive cancer center in the Mid-Atlantic region of the United States to assess the feasibility of using such devices for managing medication and medication related side-effects. We evaluated patients’ attitudes towards the design and function of smart devices and how these devices fit into their daily life. Our results may help clinicians and researchers to co-develop effective mHealth system deployments for side effect and medication management in oncology populations.
